Story
Q32 Bio Shares Fall After-Hours on $200 Million Stock Offering Plan
Q32 Bio (NASDAQ: QTTB) shares declined in after-hours trading Monday after the company announced plans for a $200 million public offering, reversing a portion of the day's dramatic gains. The move to raise capital came just hours after the stock had surged on positive results from a clinical trial.
Offering Details
In a statement released after the market close, Q32 Bio said it commenced an underwritten public offering of $200 million of its common stock and, for certain investors, pre-funded warrants. The company also intends to grant underwriters a 30-day option to purchase up to an additional $30 million in shares at the offering price, less commissions.
According to the announcement, the joint book-running managers for the offering are Morgan Stanley, Jefferies, and Cantor. Oppenheimer & Co. is also serving as a book-running manager, and H.C. Wainwright & Co. is acting as lead manager.
Market Reaction and Context
Shares of QTTB fell approximately 6% in after-hours trading following the announcement. Such offerings can dilute the ownership stake of existing shareholders, often putting downward pressure on a company's stock price in the short term.
AdThe decline stood in stark contrast to the stock's performance during regular trading hours, when it soared 90%. That rally was fueled by the company's release of positive 36-week topline results from its Phase 2a clinical trial evaluating bempikibart, a treatment for patients with severe alopecia areata.
Use of Proceeds
Q32 Bio stated that it plans to use the net proceeds from the offering for working capital and other general corporate purposes. These funds are expected to support research, clinical development, and potential commercialization efforts.
Specifically, the capital is intended to help advance its lead drug candidate, bempikibart, into future clinical trials. Q32 Bio focuses on developing therapies for autoimmune and inflammatory diseases.